Xilio Therapeutics, Inc. Stock Price, News & Analysis

Xilio Therapeutics (XLO) reported key pipeline and financial updates for Q4 and full year 2024. The company highlighted promising Phase 2 data for vilastobart, showing a 27% objective response rate in MSS CRC patients without liver metastases, with only 5% reporting colitis.

The company announced a significant collaboration with AbbVie in Q1 2025, receiving $52.0 million in upfront payments, including a $10.0 million equity investment, with potential for up to $2.1 billion in milestone payments plus royalties.

Financial highlights include: Cash position of $55.3 million as of December 31, 2024; License revenue of $6.3 million for 2024; R&D expenses decreased to $41.2 million from $52.1 million in 2023; Net loss improved to $58.2 million from $76.4 million in 2023. The company expects current cash runway into Q1 2026.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.

The company's president and chief executive officer, René Russo, Pharm.D., will engage in a fireside chat on Monday, March 3, 2025, at 9:50 am EST.

Interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's investor relations website at ir.xiliotx.com. The webcast recording will remain available on the website for 30 days after the presentation.

Xilio Therapeutics (Nasdaq: XLO) announced three preclinical programs for masked T cell engagers targeting PSMA, CLDN18.2, and STEAP1. The company also entered into a collaboration agreement with AbbVie, receiving $52.0 million in upfront payments ($42.0M cash and $10.0M equity investment).

The collaboration includes an exclusive option for AbbVie to develop masked cell engager molecules and a license for masked antibody-based immunotherapy, with potential additional payments up to $2.1 billion plus tiered royalties. Xilio's technology aims to improve T cell engager tolerability through tumor-selective activation.

Development timelines include: PSMA candidate nomination in Q3 2025 (IND in Q1 2027), CLDN18.2 candidate in Q4 2025 (IND in Q2 2027), and STEAP1 candidate in H1 2026 (IND in H2 2027). The company's cash runway has been extended into Q1 2026.

AbbVie (ABBV) and Xilio Therapeutics (XLO) have announced a collaboration and option-to-license agreement to develop novel tumor-activated immunotherapies. The partnership leverages Xilio's proprietary technology for tumor-activated biologics, focusing on masked T-cell engagers and antibody-based immunotherapies.

The agreement includes $52.0 million in total upfront payments, with a $10.0M equity investment from AbbVie. Xilio is eligible to receive up to $2.1 billion in contingent payments for option-related fees and milestones, plus tiered royalties. The collaboration aims to combine AbbVie's oncology expertise with Xilio's tumor-activation technology to develop next-generation cancer treatments with minimized systemic adverse events.

AbbVie (ABBV) and Xilio Therapeutics (XLO) have announced a collaboration and option-to-license agreement to develop novel tumor-activated immunotherapies. The partnership leverages Xilio's proprietary technology platform for developing tumor-activated biologics, including masked T-cell engagers.

The collaboration aims to combine AbbVie's oncology expertise with Xilio's technology to create next-generation cancer treatments focused on tumor-selective activation while minimizing systemic adverse events. Under the agreement terms, Xilio will receive $52.0 million in total upfront payments, including a $10.0M equity investment, and will be eligible for up to $2.1 billion in contingent payments plus tiered royalties.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to four new employees. The grants, effective February 1, 2025, consist of non-qualified stock options to purchase 83,400 shares of common stock at an exercise price of $0.705 per share, matching the closing price on January 31, 2025.

The options have a ten-year term with a vesting schedule of 25% after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (Nasdaq: XLO) announced initial Phase 2 data for vilastobart (XTX101) combined with atezolizumab in treating metastatic microsatellite stable colorectal cancer (MSS CRC). The trial showed a 27% preliminary response rate in patients without liver metastases, with three partial responses including two confirmed ones.

Key findings include decreased levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA), along with improved clinical symptoms. Among 40 treated patients, the combination demonstrated a favorable safety profile with low immune-related adverse events and only 5% reporting colitis. Of the 18 patients evaluable for response, 11 without liver metastases showed promising results, with responses ongoing at data cutoff.

The company plans to report updated Phase 2 data in mid-2025 and is seeking partnership opportunities to expand development beyond the initial MSS CRC trial.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted a non-qualified stock option to a new employee. The option, effective January 1, 2025, allows for the purchase of 60,000 shares of common stock at an exercise price of $0.955 per share, matching the company's closing price on December 31, 2024.

The stock option has a ten-year term with a vesting schedule of 25% after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted a non-qualified stock option to its new Chief Legal Officer, Caroline Hensley. The option, effective January 1, 2025, allows for the purchase of 375,000 shares of common stock at an exercise price of $0.955 per share, matching the company's closing price on December 31, 2024.

The stock option has a ten-year term with a vesting schedule where 25% of shares vest after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).